Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Julphar
UBS
McKinsey
Federal Trade Commission

Generated: June 26, 2019

DrugPatentWatch Database Preview

Patent: 9,764,033

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,764,033
Title:Formulation for anti-.alpha.4.beta.7 antibody
Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-.alpha.4.beta.7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-.alpha.4.beta.7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo.
Inventor(s): Diluzio; Willow (Westford, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Brown; Jason (Burlington, MA), Scholz; Catherine (Woburn, MA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:14/114,832
Patent Claims:see list of patent claims

Details for Patent 9,764,033

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Takeda Pharms Usa ENTYVIO vedolizumab INJECTABLE;INJECTION 125476 001 2014-05-20 ➤ Try a Free Trial Millennium Pharmaceuticals, Inc. (Cambridge, MA) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
Merck
McKesson
Chinese Patent Office
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.